Wicked Good Cardiometabolic Chat: The Clinical Essentials of Finerenone скачать в хорошем качестве

Wicked Good Cardiometabolic Chat: The Clinical Essentials of Finerenone

In episode 8 of Wicked Good Cardiometabolic Chat, Jennifer Goldman, PharmD, CDCES, BC-ADM, FCCP, professor of pharmacy practice at the Massachusetts College of Pharmacy and Health Sciences (MCPHS), and Hailey Choi, PharmD, BCACP, CDCES, associate professor of pharmacy practice at MCPHS, help bridge the gap between clinical trials and the pharmacy counter by exploring the evolving role of finerenone (Kerendia). Sitting at the critical intersection of diabetes, chronic kidney disease (CKD), and heart failure, finerenone represents a shift from simple symptom management to long-term organ protection. This conversation moves beyond the basics, addressing questions pharmacists face daily, such as: How does a non-steroidal MRA differ from traditional options like spironolactone? Where does it fit alongside ACE inhibitors, ARBs, and SGLT2 inhibitors? What do the FIDELIO-DKD and FIGARO-DKD trials actually tell us about residual risk? With two FDA-approved indications covering CKD associated with type 2 diabetes and heart failure with LVEF ≥ 40%, understanding finerenone’s unique pharmacologic profile is essential. Join our hosts as they break down the evidence, discuss potassium management, and highlight how pharmacists can ensure this therapy is used safely to slow disease progression and improve patient outcomes.